iRhythm Technologies (IRTC) Competitors $158.52 +0.59 (+0.37%) Closing price 04:00 PM EasternExtended Trading$158.54 +0.01 (+0.01%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRTC vs. ZBH, SNN, SOLV, PEN, STVN, GKOS, BLCO, SLNO, TMDX, and NVSTShould you be buying iRhythm Technologies stock or one of its competitors? The main competitors of iRhythm Technologies include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical equipment" industry. iRhythm Technologies vs. Its Competitors Zimmer Biomet Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos Bausch + Lomb Soleno Therapeutics TransMedics Group Envista iRhythm Technologies (NASDAQ:IRTC) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Which has higher earnings & valuation, IRTC or ZBH? Zimmer Biomet has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRhythm Technologies$657.23M7.75-$113.29M-$2.93-54.10Zimmer Biomet$7.83B2.64$903.70M$4.1125.38 Is IRTC or ZBH more profitable? Zimmer Biomet has a net margin of 10.51% compared to iRhythm Technologies' net margin of -14.06%. Zimmer Biomet's return on equity of 12.76% beat iRhythm Technologies' return on equity.Company Net Margins Return on Equity Return on Assets iRhythm Technologies-14.06% -90.03% -8.52% Zimmer Biomet 10.51%12.76%7.21% Which has more volatility & risk, IRTC or ZBH? iRhythm Technologies has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Does the media prefer IRTC or ZBH? In the previous week, Zimmer Biomet had 7 more articles in the media than iRhythm Technologies. MarketBeat recorded 24 mentions for Zimmer Biomet and 17 mentions for iRhythm Technologies. Zimmer Biomet's average media sentiment score of 1.22 beat iRhythm Technologies' score of 0.56 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zimmer Biomet 18 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer IRTC or ZBH? iRhythm Technologies presently has a consensus price target of $157.30, indicating a potential downside of 0.77%. Zimmer Biomet has a consensus price target of $111.44, indicating a potential upside of 6.85%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than iRhythm Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRhythm Technologies 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Zimmer Biomet 2 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.35 Do insiders & institutionals believe in IRTC or ZBH? 88.9% of Zimmer Biomet shares are held by institutional investors. 1.1% of iRhythm Technologies shares are held by insiders. Comparatively, 1.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryZimmer Biomet beats iRhythm Technologies on 12 of the 16 factors compared between the two stocks. Get iRhythm Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRTC vs. The Competition Export to ExcelMetriciRhythm TechnologiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.09B$2.06B$5.76B$9.65BDividend YieldN/AN/A3.91%4.09%P/E Ratio-54.1036.6830.7825.12Price / Sales7.755.35456.64116.46Price / CashN/A51.0625.2228.45Price / Book54.6610.369.375.95Net Income-$113.29M-$63.67M$3.26B$265.46M7 Day Performance-2.36%2.16%1.88%0.96%1 Month Performance16.35%-0.04%3.73%2.47%1 Year Performance127.50%20.92%28.93%20.24% iRhythm Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRTCiRhythm Technologies1.3242 of 5 stars$158.52+0.4%$157.30-0.8%+141.2%$5.09B$657.23M-54.102,000News CoverageZBHZimmer Biomet4.7012 of 5 stars$99.95+0.7%$111.44+11.5%-7.2%$19.66B$7.68B24.3217,000News CoveragePositive NewsSNNSmith & Nephew SNATS3.1704 of 5 stars$35.96-0.5%$28.00-22.1%+20.0%$15.83B$5.81B16.6517,349News CoveragePositive NewsAnalyst ForecastSOLVSolventum1.9322 of 5 stars$71.89-2.0%$85.75+19.3%+19.3%$12.70B$8.25B33.2822,000News CoveragePositive NewsAnalyst UpgradeInsider TradePENPenumbra4.8226 of 5 stars$239.79-0.3%$300.47+25.3%+34.0%$9.38B$1.19B63.774,500Positive NewsSTVNStevanato GroupN/A€22.14-6.3%N/A+13.2%€6.70B€1.19B41.005,521Gap DownGKOSGlaukos4.7176 of 5 stars$86.94+2.7%$127.42+46.6%-29.8%$4.85B$383.48M-52.69780Positive NewsBLCOBausch + Lomb2.206 of 5 stars$13.66+0.1%$15.56+13.9%-9.5%$4.83B$4.79B-17.5113,500Positive NewsSLNOSoleno Therapeutics4.6011 of 5 stars$85.76+4.1%$113.30+32.1%+40.6%$4.38BN/A-20.7130News CoverageAnalyst ForecastTMDXTransMedics Group2.6902 of 5 stars$127.26+11.1%$123.00-3.3%-26.2%$3.90B$441.54M65.94210NVSTEnvista3.7635 of 5 stars$20.19-0.3%$20.92+3.7%+15.8%$3.36B$2.51B63.0812,300 Related Companies and Tools Related Companies Zimmer Biomet Alternatives Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Soleno Therapeutics Alternatives TransMedics Group Alternatives Envista Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRTC) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRhythm Technologies Please log in to your account or sign up in order to add this asset to your watchlist. Share iRhythm Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access